Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C P Denton

Showing results (21-30 of 98) with videos related to

Pageof 10
Sort By:
Clinical and Experimental Rheumatology|October 3, 2009
Does long term therapy with lansoprazole slow progression of oesophageal involvement in systemic sclerosis?A Pakozdi, H Wilson, C M Black, et al.
The Journal of Investigative Dermatology|March 1, 1997
Scleroderma fibroblasts show increased responsiveness to endothelial cell-derived IL-1 and bFGFC P Denton, S Xu, C M Black, et al.
Clinical and Experimental Rheumatology|August 19, 2000
Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot studyC P Denton, K Howell, R J Stratton, et al.
Rheumatology (Oxford, England)|June 3, 2009
Digital ulcers: overt vascular disease in systemic sclerosisV Steen, C P Denton, J E Pope, et al.
The British Journal of Ophthalmology|July 19, 2005
Bilateral ischaemic retinal vasculopathy in sclerodermaM Minasian, M Stanford, E Graham, et al.
Rheumatology (Oxford, England)|April 12, 2007
Using a self-reported functional score to assess disease progression in systemic sclerosisK Serednicka, A E Smyth, C M Black, et al.
Clinical and Experimental Rheumatology|August 2, 2003
Assessment of lung involvementM Matucci-Cerinic, S D'Angelo, C P Denton, et al.
Rheumatology (Oxford, England)|October 16, 2001
Anti-fibrillarin antibodies in systemic sclerosisV J Tormey, C C Bunn, C P Denton, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 4, 2016
ReplyG A Margaritopoulos, K M Antoniou, C P Denton, et al.
Annals of the Rheumatic Diseases|July 31, 2007
Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosisS I Nihtyanova, G M Brough, C M Black, et al.
Pageof 10

Showing results (21-30 of 98) with videos related to

Sort By:
Pageof 10
Clinical and Experimental Rheumatology|October 3, 2009
Does long term therapy with lansoprazole slow progression of oesophageal involvement in systemic sclerosis?A Pakozdi, H Wilson, C M Black, et al.
The Journal of Investigative Dermatology|March 1, 1997
Scleroderma fibroblasts show increased responsiveness to endothelial cell-derived IL-1 and bFGFC P Denton, S Xu, C M Black, et al.
Clinical and Experimental Rheumatology|August 19, 2000
Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot studyC P Denton, K Howell, R J Stratton, et al.
Rheumatology (Oxford, England)|June 3, 2009
Digital ulcers: overt vascular disease in systemic sclerosisV Steen, C P Denton, J E Pope, et al.
The British Journal of Ophthalmology|July 19, 2005
Bilateral ischaemic retinal vasculopathy in sclerodermaM Minasian, M Stanford, E Graham, et al.
Rheumatology (Oxford, England)|April 12, 2007
Using a self-reported functional score to assess disease progression in systemic sclerosisK Serednicka, A E Smyth, C M Black, et al.
Clinical and Experimental Rheumatology|August 2, 2003
Assessment of lung involvementM Matucci-Cerinic, S D'Angelo, C P Denton, et al.
Rheumatology (Oxford, England)|October 16, 2001
Anti-fibrillarin antibodies in systemic sclerosisV J Tormey, C C Bunn, C P Denton, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 4, 2016
ReplyG A Margaritopoulos, K M Antoniou, C P Denton, et al.
Annals of the Rheumatic Diseases|July 31, 2007
Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosisS I Nihtyanova, G M Brough, C M Black, et al.
Pageof 10